A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis | Zendy

Lena M. Biehl | Zendy; Jörg Janne Vehreschild | Zendy; Blasius Liss | Zendy; Bernd Franke | Zendy; Birgid Markiefka | Zendy; Thors﻿ten Persigehl | Zendy; Vanessa Bücker | Zendy; Hilmar Wisplinghoff | Zendy; Christof Scheid | Zendy; Oliver A. Cornely | Zendy; Maria J. G. T. Vehreschild | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis

Author(s) -

Lena M. Biehl,

Jörg Janne Vehreschild,

Blasius Liss,

Bernd Franke,

Birgid Markiefka,

Thorsten Persigehl,

Vanessa Bücker,

Hilmar Wisplinghoff,

Christof Scheid,

Oliver A. Cornely,

Maria J. G. T. Vehreschild

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw199

Subject(s) - posaconazole , medicine , incidence (geometry) , micafungin , itraconazole , neutropenia , cohort , surgery , chemotherapy , amphotericin b , antifungal , dermatology , physics , optics

Antifungal prophylaxis is recommended for haematological patients at high risk of invasive fungal infections (IFIs). Incidence, optimal therapeutic management and outcome of breakthrough IFIs (bIFIs) are largely unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research